Sanofi successfully prices EUR 1 billion bond issue
29 August 2013 | By Sanofi
Sanofi announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%...
List view / Grid view
29 August 2013 | By Sanofi
Sanofi announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%...
5 August 2013 | By Sanofi
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide...
31 July 2013 | By Sanofi
Sanofi announced the appointment of two new members to the Executive Committee, effective September 1st, 2013...
8 July 2013 | By Just:: Health PR
Sanofi is delighted to announce the winners of its 2013 Patient Group Bursary scheme...
28 June 2013 | By Sanofi
"Today’s CHMP opinions set the stage for the approval of two important new treatment options..."
28 June 2013 | By Sanofi
Japan’s MHLW has approved the manufacturing and distribution of Lyxumia®...
22 June 2013 | By Sanofi
Topline results of EDITION II consistent with EDITION I findings...
19 June 2013 | By Sanofi
Preclinical program of translational research to identify new target proteins...
18 June 2013 | By Sanofi
"an important opportunity for Sanofi to share significant data..."
5 June 2013 | By Sanofi
ORIGIN was a landmark, seven-year clinical trial...
3 June 2013 | By Sanofi
Sanofi announced topline results of two Phase 3 clinical studies...
23 May 2013 | By Sanofi
Sanofi is pleased to announce the appointment of David Loew, effective July 1st , 2013.
17 May 2013 | By Sanofi
The French ministerial mission has presented the conclusions of its report regarding the Sanofi Research site in Toulouse, France...
15 May 2013 | By Sanofi
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials...
2 May 2013 | By Sanofi
A new commercial organization to better align with its business priorities...